Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib
Sponsor: Hunan Cancer Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.